Brensocatib Becomes First Approved Therapy for Bronchiectasis, Expanding Treatment Options: James D. Chalmers, MBChB, PhD

James D. Chalmers, MBChB, PhD, explains that the ASPEN trial findings show that brensocatib reduces exacerbations, slows lung function decline at higher doses, and offers clinicians a long-awaited evidence-based treatment option.